Document is current
Any future updates will be listed below
-
Authors
Hosoi, Tatsuya
Yunoki, Makoto
Tanaka, Shiro
Hagino, Hiroshi
Mori, Satoshi
Soen, Satoshi
Ogawa, Sumito https://orcid.org/0000-0002-5935-276X
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000015573 at UMIN JapanDocuments that mention this clinical trial
Evaluation of the fracture prevention effects of teriparatide and alendronate in patients with frailty: a sub-analysis of the Japanese osteoporosis intervention trial-05
https://doi.org/10.1007/s00774-025-01610-1
-
Funding
Funding for this research was provided by:
Public Health Research Foundation (-)
Asahi Kasei Pharma Corporation (-)
The University of Tokyo
- License Information
-
More Information
Article History
Received: 14 January 2025
Accepted: 2 May 2025
First Online: 27 May 2025
Declarations
:
: T Hosoi declare no competing interests. M Yunoki declare no competing interests. S Tanaka has received lecture fee from Bayer Japan, MSD K.K., Amgen Astellas BioPharma K.K., JMDC Inc. and Research Institute of Healthcare Data Science. He has received consultation fee from Boehringer Ingelheim and Daiichi Sankyo Co., Ltd. He has received outsourcing fee from Public Health Research Foundation. He has received research grants from the Japan Agency for Medical Research and Development, the Japanese Ministry of Health, Labour and Welfare, the Japanese Ministry of Education, Science and Technology, and Novo Nordisk. He engaged in a research project of the Japan Agency for Medical Research and Development. H Hagino received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Mochida Pharma Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd. S Mori declare no competing interests. S Soen has received consulting fees, speaking fees, and/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mochida Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd. S Ogawa declares no competing interests.
